Member Info for Wigwammer

LOL. Our chartist friend has called around 15 of the last 1 pull backs. Still waiting for any empirical proof TA works.. “ Despite being ridiculed often , our chartist friend has called it correctly”…. IMO DYOR GLA

Perhaps better to review your own approach, bootnk. There are holders here who have benefitted in 2025 from delivery of science advancement, delivery of funding, delivery of patent application and extending partnership discussions. If you are only ever going to jump in to shares after they have multiplied - and then get scared out in a dip - then I doubt this is a route to riches. Perhaps a bit of self reflection would help. IMO DYOR GLA

On 26th November 9.10am, OTM posted “Added some more. Another 140,000 just now” … People attack you across multiple boards because you’re an idiot, and the only certainly here is that you will always claim to be right :)

The simple calculation that rog appears incapable of making, is that with a £35m market cap the deal may not have to be huge to be highly lucrative to IMM holders. On the other hand if the deal is huge then all the better. Rog is not very good at weighing things up, which is why he repeatedly flips and flops… IMO DYOR GLA

It sounds like bootnk is also now out, and I genuinely hope he didn’t lock in a large loss. GLA DYOR IMO

It is certainly good to hear who has been selling and forcing the price down. It is also good to hear that several are now finished and out … GLA IMO DYOR

Ah spanny is still sceptical. Good sign. He wasn’t sure at 2p either. Handy thing for spanny is that with only £20 to invest he can change direction sharpish :)

The CRO selected for the first ph3 trial was announced in Jan 2015, with recruitment starting in Dec 2015 and dosing in Feb 2016. So a pretty short gap between CRO announcement and dosing (13 months). But this time round the CRO was announced in December 2023, so it is quite possible that a large part of the preparation work for the trial has already been undertaken. Hopefully we get clarity if/when the complete deal structure is announced… IMO DYOR GLA

If p140 is recognised in the industry as having immense potential then both immupharma and avion will have played blinders. And if avions market value is currently similar to immupharma’s ( c£35m) then the owners/shareholders of both would stand to do very well. P140 is a late stage asset in potentially multiple blockbuster indications. IMM own the entire rights outside the US and have an agreement to earn tiered royalties of up to 17% on all sales in the US across all indications, with the trials funded externally. The only pay away is a relatively small commitment to the CNRS. This is why I have held the shares for two years, while others have been distracted by all kinds of worries and fears. It’s about recognising woods from trees… IMO GLA DYOR

That’s great, xviolet, and I hope you get an interesting response. I recall your dd and risk management causing you to be very nervous and unsure around the 2p levels also, and we know what happened to the share price after that. Everyone has their own approach… IMO GLA DYOR

Well if you believe that question is a good one, xviolet, then do send it to immupharma and let us know the result. There’s a good chap.. :)

Oh i don’t think there’s much guesswork involved, xviolet. Just a little common sense :)

So the Lupuzor trial is either funded by Avion, or Avion breach the contract and IMM are likely free to pass the partnership to an entity that can afford it. I don’t see the issue.. IMO DYOR GLA

Gosh. Inability to meet the obligation to fund the Lupuzor trial would be a serious breach of contract terms, and immupharma would likely be free to seek remedial action :) … IMO GLA IMHO

From AI : “ Avion offered ImmuPharma tiered double-digit royalties of up to 17% for Lupuzor, based on pre-specified annual U.S. sales targets. This was part of the license and development agreement signed in November 2019 for the exclusive rights to the drug in North America. ”

One should also consider that with a circa £35m market cap - even if Avion were to take up rights across all 50 indications in the US and run related trials - this would likely be an outcome highly beneficial to IMM holders. The sales royalties on the original lupus agreement ran to mid/high teens (from memory)… IMO DYOR GLA

Surely the point is that the avion agreement was announced in 2019, prior to the research undertaken on type M, related diagnostic and patent application. It would seem to be in both immupharma and avion’s interest to come to a mutually beneficial arrangement, and perhaps this will form part of the new deal. IMO DYOR GLA

Lollywally neither added at 2p or sold at 10p+. He has been here daily for 2+ years, deciding nothing and demonstrating all the acumen of a brick :)

Yes Rog really should reflect on how he manages his own assets, before commenting on the business acumen of others. Flip flop flip flop… I suspect the shares are under pressure because some large private investor (who likely bought too much at double the current price) is now trying to dump with volume. But there isn’t any volume. Ah well - it is these flip floppers that create nice opportunities for the rest of us. IMO DYOR GLA

“Tim mentions other things in development that they don't talk about.... yes they don't talk about them... so what are they.... ”… its not hard to go to the website and select the pipeline page.. give it a go